Abstract
Drug development is being continuously scrutinised for its lack of productivity. Novel drug development is associated with high costs, high failure rates and lengthy development process. These downfalls combined with a huge demand in blood cancer for new therapeutic treatments have led many to consider the method of drug repurposing. Finding new therapeutic indications for already established drug substances is known as redirecting, repositioning, reprofiling, or repurposing of drugs. Off-patent and on-patent drugs can be screened for additional targets and new indications thus bringing them to clinical trials at a faster pace. This approach offers smaller research groups, such as those that are academic based, into the drug development industry. Drug repurposing can make use of previously published data concerning dosage, toxicology and mechanism of activity.
| Original language | English |
|---|---|
| Pages (from-to) | 1267-1276 |
| Number of pages | 10 |
| Journal | Annals of Hematology |
| Volume | 94 |
| Issue number | 8 |
| Early online date | 07 Jun 2015 |
| DOIs | |
| Publication status | Published - Aug 2015 |
Access to Document
- Repurposing medicinal compounds for blood cancer treatment
© 2015 The Author(s) This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.